{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:44:26Z","timestamp":1787013866910,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the effectiveness of intravitreal conbercept and ranibizumab treatment for retinopathy of prematurity (ROP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, the date of patients with ROP treated with intravitreal conbercept or ranibizumab from July 2012 to March 2018 with at least 12\u00a0months of follow\u2010up at the Eye Center in People\u2019s Hospital of Peking University were analysed. Regression, progression or recurrence and peripheral retina vascularization were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 283 eyes (145 infants) with conbercept treatment and 916 eyes (480 infants) with ranibizumab treatment were enrolled. In zone I ROP and aggressive posterior ROP (APROP), the recurrence prevalence was 49.09% (108\/220 eyes) and 28.57% (10\/33 eyes), and the recurrence interval was 7.87\u00a0\u00b1\u00a00.65 (5.5\u20139.5) weeks and 10.6\u00a0\u00b1\u00a01.53 (10.5\u201313) weeks in the ranibizumab and conbercept groups, respectively. In zone II ROP disease, the recurrence prevalence was 23.56% (164\/696 eyes) and 13.31% (33\/248 eyes), and the interval of recurrence was 8.40\u00a0\u00b1\u00a00.88 (6\u201310.5) weeks and 11.4\u00a0\u00b1\u00a01.35 (11\u201313.5) weeks in the ranibizumab and conbercept groups, respectively. The recurrence prevalence was significantly higher with ranibizumab in Zone I ROP and APROP (p\u00a0=\u00a00.006) and Zone II ROP (p\u00a0&lt;\u00a00.001), and the recurrence interval was significantly longer in the conbercept group than that in the ranibizumab (p\u00a0&lt;\u00a00.001). There was no significant difference in the rate of retinal vascularization (p\u00a0=\u00a00.441).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Conbercept and ranibizumab are effective for treating ROP. Compared with ranibizumab, conbercept resulted in less recurrence and longer treatment intervals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/aos.14460","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:39:49Z","timestamp":1588991989000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity"],"prefix":"10.1111","volume":"98","author":[{"given":"Yong","family":"Cheng","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital Eye diseases and Optometry Institute Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases Department of Ophthalmology &amp; Clinical Centre of Optometry College of Optometry Peking University Health Science Center Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital Eye diseases and Optometry Institute Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases Department of Ophthalmology &amp; Clinical Centre of Optometry College of Optometry Peking University Health Science Center Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Linghu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital Eye diseases and Optometry Institute Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases Department of Ophthalmology &amp; Clinical Centre of Optometry College of Optometry Peking University Health Science Center Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-4125","authenticated-orcid":false,"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital Eye diseases and Optometry Institute Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases Department of Ophthalmology &amp; Clinical Centre of Optometry College of Optometry Peking University Health Science Center Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449530"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311662"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1522"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28987-6"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm721"},{"key":"e_1_2_5_7_1","first-page":"467","article-title":"Microglia and macrophages are increased in response to ischemia\u2010induced retinopathy in the mouse retina","volume":"12","author":"Davies MH","year":"2006","journal-title":"Mol Vis."},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.3858\/emm.2012.44.1.025"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.10.032"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37264"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2016.1196709"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.03.018"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001763"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308828"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.09.002"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_2_5_18_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3928\/01913913-20131112-02","article-title":"Diode laser photocoagulation for retinopathy of prematurity: outcomes after 7 years of treatment","volume":"51","author":"Nicoara SD","year":"2014","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.01.022"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2584"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304109"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.63"},{"key":"e_1_2_5_24_1","first-page":"37","article-title":"Recombinant anti\u2010vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys","volume":"14","author":"Zhang M","year":"2008","journal-title":"Mol Vis"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9718-9"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.14460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14460","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T17:57:25Z","timestamp":1693850245000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/aos.14460"],"URL":"https:\/\/doi.org\/10.1111\/aos.14460","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"2019-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}